2019 Clinic Provider Relationship 
Annals of Family Medicine
NOVEMBER 20, 2024
Despite efforts to improve patient-clinician relationships, access to care, and healthcare workflows, annual rates of missed appointments (MA) in the U.S Objective To evaluate the association between patient, health system, geosocial, and environmental factors on the likelihood of MA in Family Medicine clinics. for CA, 0.85
Today's Hospitalist
MAY 9, 2025
Since the mid-1990s, our capacity for innovation has never stopped as hospitalists navigate a complex landscape of acute illnesses, interprofessional collaborations and the imperative to provide efficient, high-quality care. Yet this expansion has come with a significant administrative burden, particularly that of clinical documentation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Clinical Problem Solvers
OCTOBER 18, 2022
Our guests remind us to think critically about our role in the carceral system and in imposing systems of control and punishment within clinical settings. Providing communities with the resources they need to survive, such as educational opportunities, jobs, and quality healthcare, will eliminate the need for incarceration.
FDA Law Blog
OCTOBER 2, 2023
The eagerly anticipated guidance, Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence (i.e., Instead, FDA’s determination of whether a single study plus confirmatory evidence could provide substantial evidence is to be “based on relevant science.”
CDOCS
MARCH 15, 2021
Patients depend on our clinical knowledge as well as our recommendations and relationships with our specialist partners.</span></span></p> Nelson further explains, “I believe a key component to success for case acceptance is providing education to my staff and the offices I work with.
FDA Law Blog
MAY 8, 2023
FDA recommends that PCCPs specify only a “limited number” of modifications but does not provide a limit on the number of modifications that can be included. If the proposed performance evaluation methods are different from the original methods used, the manufacturer should describe the differences and provide a justification for the changes.
FDA Law Blog
OCTOBER 14, 2021
Rather, FDA seems intent on regulating RAS devices almost as if they were therapeutics responsible for long term clinical outcomes. It is well out of bounds for FDA to regulate them as if they were a determinant of long term clinical outcomes. In this safety communication, FDA states: The U.S. The question answers itself. 21 U.S.C. §
Expert insights. Personalized for you.
130 
Let's personalize your content